Polycythemia Vera Classification
Polycythemia vera is a BCR-ABL1-negative myeloproliferative neoplasm (MPN) characterized by clonal proliferation of hematopoietic stem cells, resulting in excessive red blood cell production. 1
Disease Classification
Polycythemia vera belongs to the category of chronic myeloid neoplasms, specifically within the myeloproliferative neoplasm family. This classification distinguishes it from reactive (secondary) causes of erythrocytosis by its clonal, malignant nature 2, 3.
Key Defining Features
The disorder is fundamentally a clonal hematopoietic malignancy with these characteristics:
- Genetic basis: Driven by acquired JAK2 mutations (V617F in >95% of cases, or exon 12 mutations in the remainder) 1, 3
- Pathophysiology: Constitutive activation of the JAK-STAT signaling pathway leads to uncontrolled proliferation 3
- Hematopoietic pattern: Panmyelosis with trilineage growth (erythroid, granulocytic, and megakaryocytic proliferation) 1
Distinction from Other Blood Disorders
PV is specifically classified as a BCR-ABL1-negative MPN, which separates it from chronic myelogenous leukemia (CML). The JAK2 mutation provides definitive proof that the proliferation is clonal rather than reactive, eliminating consideration of secondary polycythemia 1.
The WHO classification groups PV alongside other BCR-ABL1-negative MPNs including essential thrombocythemia and primary myelofibrosis, all of which can harbor JAK2 mutations but have distinct clinical presentations 1.
Clinical Significance of Classification
Understanding PV as a chronic hematological malignancy rather than a benign condition is critical because:
- It carries risk of life-threatening thrombotic complications
- It can transform to myelofibrosis or acute myeloid leukemia
- It requires long-term cytoreductive therapy, not just symptomatic management 4, 5
The malignant nature of this clonal stem cell disorder fundamentally distinguishes it from secondary (reactive) causes of elevated red blood cell counts, which are non-clonal responses to physiologic stimuli like hypoxia or erythropoietin-secreting tumors.